PDS Biotechnology Corporation Common Stock
$0.99
$0.41 (+69.25%)
$0.62Day Range$1.06
Key Statistics
Market Cap
$71.79M
Shares Outstanding
72.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 1, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$0.65
Day High
$1.06
Day Low
$0.62
Volume
196.52M
VWAP
$0.86
Prev Close
$0.59
Transactions
--
Acc. Volume
--
About PDS Biotechnology Corporation Common Stock
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
PHARMACEUTICAL PREPARATIONSSIC 283421 employees303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540800-208-3343IPO Oct 1, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001472091
- Composite FIGI
- BBG004NCDK82
- Share Class FIGI
- BBG004NCDKL7
- Ticker Root
- PDSB
- SIC Code
- 2834
About PDS Biotechnology Corporation Common Stock (PDSB) Stock
PDS Biotechnology Corporation Common Stock (PDSB) closed the 2026-09-16 session at $0.99, up 69.25% versus the previous close (+0.41). The stock opened at $0.65 and traded between $0.62 and $1.06 during that session. Session trading volume was 196.5M shares. The volume-weighted average price (VWAP) is $0.86.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
PDS Biotechnology Corporation Common Stock has a market capitalization of $71.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PDSB is listed on the XNAS exchange. The company employs approximately 21 people. PDS Biotechnology Corporation Common Stock is headquartered in PRINCETON, NJ. The recorded listing date is 2015-10-01.
On this page you can find market PDSB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.